Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Gains IP for Breast Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Atossa Genetics today announced it has acquired intellectual property from the Dr. Susan Love Research Foundation covering a biomarker test for breast cancer.

Atossa has acquired all ownership rights to US Patent No. 7,879,614 and pending US application 11/958,597. Both patents cover the manufacture, use, and sale of a biomarker test for the analysis of carbohydrates contained in nipple aspirate fluid using a sensitive detection reagent such as a Schiff's reagent.

Atossa is paying an upfront fee as well as patent-based royalties on aggregate net sales in the countries with issued patents, it said. No further financial details about the transaction were disclosed.

In a clinical trial of nipple aspirate fluid from 28 women 30 to 52 years old at the Breast Care Clinic at the University of California, San Francisco, the test was positive for all 12 women with known cancer and negative with 12 of 16 women without cancer.

"We intend to continue the clinical research needed to determine if these early results are valid and whether the biomarker can form the basis of a useful clinical screening test," Steven Quay, chairman and CEO, of Atossa said.

Based in Seattle, Atossa develops molecular diagnostics for breast cancer. Last month the firm announced it raised $6.6 million in a private placement with accredited investors. Proceeds will be used to create a commercial manufacturing process for its Mammary Aspirate Specimen Cytology Test System, or MASCT.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.